Hints and tips:
...Mani Foroohar, an analyst at Leerink Partners, said Moderna had been “spending aggressively” in the hope that the market for Covid-19 vaccines rebounds, and that in many countries, including the UK, the...
...Eli Lilly’s tirzepatide drug had less than 10 per cent absolute weight reduction at all doses after its late-stage trial, noted Thomas Smith, an analyst at Leerink Partners....
...Under a strategic expansion led by Becker, who took over as chief executive in 2011, it acquired investment bank Leerink Partners in 2019 and wealth manager Boston Private in 2021....
...“There’s been a noticeable, dramatic improvement in sentiment among investors,” said Rahul Chaudhary, head of healthcare equity capital markets at Leerink Partners....
...“There were companies that, if we were all honest with ourselves, probably weren’t ready to be public,” said Rahul Chaudhary, head of healthcare equity capital markets at Leerink Partners....
...Analysts at Leerink Partners said there was a risk of even lower revenue from the vaccine than their own forecasts in the fourth quarter because at present they assume there will be a “massive uptick in...
...The division will be renamed Leerink Partners, returning to a brand that was in existence four years ago....
...This month Mineralys Therapeutics raised $118mn, led by European private equity firm Andera Partners and RA Capital Management, a Boston-based investment manager....
...Merck, which developed molnupiravir with partner Ridgeback Biotherapeutics, said it was in active discussions with regulators with the aim of bringing the drug to patients in Europe as quickly as possible...
...The bank had been on a blistering growth trajectory in recent years, almost tripling headcount between 2020 and 2023 through a series of acquisitions, including investment bank Leerink Partners, private...
...Even with that, pharma companies are still sitting on billions of dollars of cash “because they’ve been some of the winners of the pandemic,” said James Langston, a partner at law firm Cleary Gottlieb....
...PlantForm, a Canadian biotech company, and Sydney-based NeuClone Pharmaceuticals are already working with partners in Brazil and India to launch “biosimilars” that are almost identical to Keytruda....
...“Pfizer are already dominating the Covid vaccine race and are likely to consolidate their position in the coming months,” said Geoffrey Porges, analyst at SVB Leerink....
...bank Centerview Partners....
...Pfizer’s shares are up only 12 per cent since the start of 2020, a paltry gain compared with those of its partner BioNTech, which have risen more than 500 per cent, or rival Moderna, which are 1,700 per...
...“If [mRNA] does work, you could cede the whole market to Moderna or Pfizer,” said Geoffrey Porges, an analyst at healthcare-focused investment bank SVB Leerink....
...Cigna, the insurance and pharmacy group, saw its stock fall 6 per cent over the week on fears Amazon would upend the industry — despite being an exclusive partner with Amazon on the new endeavour....
...Geoffrey Porges, an analyst at SVB Leerink, said the additional supply was “very good news economically, socially, and medically”....
...AstraZeneca became Oxford university’s partner for the development of a vaccine for coronavirus earlier this year....
...AstraZeneca and manufacturing partners around the world, such as India’s Serum Institute, hope to produce up to 3bn doses next year....
...He had to search for a partner who had the dollars he needed. His first stop was Pfizer because they had already worked together....
...Analysts at SVB Leerink said at the weekend that the price may need to be closer to $200 to soothe investors....
...Geoffrey Porges, an analyst at SVB Leerink, estimated the shot could generate about $3.5bn next year, split between Pfizer and BioNTech....
...Mani Foroohar, an analyst at SVB Leerink, said the market might become “messy [and] competitive”, if a number of vaccines succeed....
...In a range of about $50 to $60 for a course — that is, $25-$30 per dose — it appears to be higher than that agreed by Pfizer and its German partner BioNTech last week in a pre-order deal with the US government...
International Edition